secwatch.observer — SEC 8-K summary
======================================

Issuer:     HeartSciences Inc. (HSCS)
CIK:        0001468492
Form:       8-K
Filed at:   2025-07-14T23:59:59+00:00
Accession:  0001213900-25-063491
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HeartSciences expands equity plan to 1M shares, grants RSUs and options tied to FDA clearance
--------------------------------------------------------------------------------

- Board approved amendment to 2023 Equity Incentive Plan increasing maximum shares to 1,000,000; subject to shareholder vote at next annual meeting.
- CEO Andrew Simpson received 68,750 RSUs; COO Mark Hilz received 56,250 RSUs; vest upon FDA clearance of MyoVista Device or Change of Control.
- Granted options: CEO 275,000, COO 225,000, CFO 25,000 at $4.37/share, vesting over three years with acceleration on FDA clearance.
- Non-employee directors each received 25,000 options at $4.37.
- As of July 11, 2025, raised $1.7M from Reg A offering (487,701 units) and exchanged $855K debt for 233,229 shares; total shares outstanding ~1.555M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468492/000121390025063491/0001213900-25-063491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468492/000121390025063491/ea0248765-8k_heart.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-063491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer